معرفی
Lars Wallentin is a Professor at the Department of Medical Sciences, Cardiology section, at Uppsala University, and also holds a position at the UCR-Uppsala Clinical Research Center. His academic work focuses on advancing cardiovascular medicine through research on atrial fibrillation, anticoagulation therapy, and biomarker development for risk stratification.
Professor Wallentin's research interests center on cardiology with specific expertise in atrial fibrillation management, anticoagulation therapy, cardiovascular biomarkers, and clinical trial methodology. His work has significantly contributed to understanding stroke prevention strategies in atrial fibrillation patients, risk stratification using novel biomarkers, and optimizing anticoagulant therapy across different patient populations including elderly patients and those with comorbid conditions. His research spans both clinical and translational aspects, connecting laboratory findings with patient outcomes.
His recent publications demonstrate a consistent focus on cardiovascular outcomes research, particularly in the areas of atrial fibrillation management and anticoagulation therapy. The research shows a strong emphasis on biomarker development for risk prediction, with particular attention to stroke prevention and heart failure risk assessment in atrial fibrillation patients. His work also extends to registry-based studies and the development of standardized outcome measures through initiatives like EuroHeart, which aims to create unified registries for heart care evaluation across Europe.
Professor Wallentin has been actively involved in several major clinical trials including ARISTOTLE, COMBINE-AF, SWEDEHEART, and ISCHEMIA, where he has contributed to advancing our understanding of cardiovascular disease management. His international collaborations are evident through his numerous co-authorships with researchers across Europe and North America, reflecting the global impact of his work in cardiovascular medicine.
